Pivotal Clinical Trials: Frequently Asked Questions (Sofpromed).
What is a pivotal clinical trial?
A pivotal clinical trial is a clinical study seeking to demonstrate the efficacy of a new drug in order...
Adding Cardiol Therapeutics (CRDL) $0.59 to Watch List.
Adding to 2023 Biotech Stock Review Watch List. We Think This One Has Legs.
Starting Due Diligence Now.
It takes us about 15 minutes after talking...
Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?
After dropping 94% from post IPO high from $19.45, a loss exceeding $3 billion and change, ATAI is in the early stages of recovery (in our opinion)...
The Ketamine Endgame. Silo Pharmaceutical (SILO).
James Kuo, M.D. the Vice President of R&D for Silo Pharma (SILO) will speak at the 3rd Annual Psychedelic Therapeutics and Drug Development Conference.
Dr....
The Ketamine Cure (NY Times)
The once-taboo drug has been repurposed to treat depression and is even available for delivery. But how safe is it?
By David Dodge NYT | Published Nov....
The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s Novel Topical Ketamine Delivery.
Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted to Relieve PTSD Symptoms Within Minutes and Negate Side Effects
FT. LAUDERDALE, FL /...
Ardelyx (ARDX) Resubmits New Drug Application to FDA.
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize...
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.
LIVE QUOTE
Ardelyx Enters the Danger Zone* With Tenapanor.
The company produced favorable (albeit very technical) information (data) at the National Kidney Foundation 2023 Spring Clinical...
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment...
Topline Results anticipated by the end of Q2 2023
CRANFORD, N.J. , April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced...
And We Have a $26.4 Billion Winning Trifecta!
THREE PREVIOUS WINNERS*
Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired by Gilead Sciences (GILD)
Dicerna (DRNA) $3.30 to $38.25 up...
Latest article
Annette L. Redmond Joins Strategic Advisory Board at Sekur Private Data (SWISF).
Former U.S. State Department Deputy Assistant Secretary
Decorated intelligence and cybersecurity executive with four decades of U.S. government leadership joins Sekur to advise on secure...
10X Alerts: Sekur Private Data (SWISF) Pushes SekurOne Closer to Market With First International...
Sekur has completed its first domestic and international encrypted calls on SekurOne and launched the platform’s voice, email, messenger, and VPN capabilities on Android...
Could a Record El Niño Ignite the Next Vaccine Trade?
Chikungunya, Dengue Fever, Rift Valley Fever and Zika
The Coming El Niño: An Overlooked Catalyst for Vaccine Stocks?
Investors obsess over interest rates, tariffs and AI....
